drugset / Trial / NCT02132117

Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea

NCT02132117

Phase 3 Completed 445 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and efficacy of oxymetazoline hydrochloride (HCl) cream 1.0% (AGN-199201) once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.

Timeline

Start
2014-06
Primary completion
2015-04
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxymetazoline Other / unclassified 1 % Topical

Indications